Study to see if GSK2110183 with chemotherapy can treat ovarian cancer

• Research type

  Research Study

• Full title

  An Open-Label Phase I/II Study of GSK2110183 in Combination with Carboplatin and Paclitaxel in Subjects with Platinum-Resistant Ovarian Cancer

• IRAS ID

  108459

• Contact name

  Sarah Blagden

• Sponsor organisation

  Octagon Research Solutions, Inc.

• Eudract number

  2012-002483-27

• Duration of Study in the UK

  2 years, 0 months, 0 days

• Research summary

  There are two phases being conducted in this clinical trial. The first phase of the trial will help determine the safety and tolerability of GSK2110183 used in patients with recurrent ovarian cancer, GSK2110183 is a new drug which will be used in conjunction with current chemotherapy (other drugs used to treat cancer such as Carboplatin and paclitaxel) in patients with platinum-resistant ovarian cancer. This form of cancer is resistant to current chemotherapy and it is thought that the combination of GSK2110183 (A drug which blocks certain protein cells which is also known as an AKT Inhibitor) and chemotherapy will reverse the resistance in the cancer enabling effective treatment of the disease.
  Phase II of this trial will be used to evaluate how effective the new drug (GSK2110183) administered in combination with carboplatin and paclitaxel is within patients with recurrent platinum-resistant ovarian cancer.

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  12/LO/1173

• Date of REC Opinion

  7 Nov 2012

• REC opinion

  Further Information Favourable Opinion